Reversal of cardiac fibrosis and related dysfunction by relaxin experimental findings

Annals of the New York Academy of Sciences

Volumn 1160, Issue , 2009, Pages 278-284

  Du, Xiao Jun ^a   Xu, Qi ^a   Lekgabe, Edna ^a,b   Gao, Xiao Ming ^a   Kiriazis, Helen ^a   Moore, Xiao Lei ^a   Dart, Anthony M ^a   Tregear, Geoffrey W ^b   Bathgate, Ross A D ^b   Samuel, Chrishan S ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Animal models; Antifibrosis therapy; Cardiac fibrosis; Cardiac function; Relaxin

Indexed keywords

ANTIFIBROTIC AGENT; RELAXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; GENE TARGETING; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; NONHUMAN;

ANIMALIA; MUS; RODENTIA;

EID: 64549159776     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03780.x     Document Type: Conference Paper

References (33)

1. Brown, R.D., S.K. Ambler, M.D. Mitchell, et al. 2005. The cardiac fibroblast: Therapeutic target in my-ocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 45: 657-687.
2. Spach, M.S. 2007. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ. Res. 101: 743-745.
3. Miragoli, M., N. Salvarani & S. Rohr. 2007. My-ofibroblasts induce ectopic activity in cardiac tissue. Circ. Res. 101: 755-758.
4. Nishio, M., Y. Sakata, T. Mano, et al. 2007. Therapeutic effects of angiotensin type I receptor blocker at an advanced stage of hypertensive diastolic heart failure. J. Hypertens. 25: 455-461.
5. Mottram, P.M., B. Haluska, R. Leano, et al. 2004. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110: 558-565.
6. Funder, J.W. 2008. Translational research goes both ways: Lessons from clinical studies. Clin. Exp. Pharmacol. Physiol. 25: 526-529.
7. Samuel, C.S., E.N. Umemori, I. Mookerjee, et al. 2004. Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145: 4125-4133.
8. Du, X.J., C.S. Samuel, X.M. Gao, et al. 2003. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: A gender-specific phenotype. Cardiovasc. Res. 57: 395-404.
9. Lekgabe, E.D., H. Kiriazis, C. Zhao, et al. 2005. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46: 412-418.
10. Samuel, C.S., T.D. Hewitson, Y. Zhang, et al. 2008. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 149: 3286-3293.
11. 2-adrenergic receptors in the heart. Cardiovasc. Res. 47: 448-454.
12. Bathgate, R.A.D., E.D. Lekgabe, J.T. McGuane, et al. 2008. Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol. Cell. Endocrinol. 280: 30-38.
13. Zhang, J., Y.F. Qi, B. Geng, et al. 2005. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 26: 1632-1639.
14. Dschietzig, T., C. Richter, C. Bartsch, et al. 2001. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 15: 2187-2195.
15. Xu, Q., E.D. Lekgabe, X.M. Gao, et al. 2008. Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis. Endocrinology 149: 764-782.
16. Gao, X.M., Q. Xu, H. Kiriazis, et al. 2005. Mouse model of post-infarct ventricular rupture: Time course, strain- and gender-dependency, tensile strength and histopathology. Cardiovasc. Res. 65: 469-477.
17. Fang, L., X.M. Gao, X.L. Moore, et al. 2007. Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J. Mol. Cell. Cardiol. 43: 535-544.
18. Gnecchi, M., H. He, O.D. Liang, et al. 2005. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 11: 367-368.
19. Guan, K. & G. Hasenfuss. 2007. Do stem cells in the heart truly differentiate into cardiomyocytes? J. Mol. Cell. Cardiol. 43: 377-387.
20. Du, X.J. 2007. Remodelling "hostile" milieu of diseased myocardium via paracrine function of transplanted cells or relaxin. J. Cell. Mol. Med. 11: 1101-1104.
21. Unemori, E.N., M. Lewis, J. Constant, et al. 2000. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen. 8: 361-370.
22. Perna, A.M., E. Masini, S. Nistri, et al. 2005. Novel drug development opportunity for relaxin in acute myocardial infarction: Evidences from a swine model. FASEB J. 19: 1525-1527.
23. Moore X.L., S.L. Tan, C.Y. Lo, et al. 2007. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 148: 1582-1589.
24. Formigli, L., F. Francini, A. Tani, et al. 2005. Mor-phofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment. Am. J. Physiol. Cell Physiol. 288: C795-C804.
25. Formigli, L., A.M. Perna, E. Meacci, et al. 2007. Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling. J. Cell. Mol. Med. 11: 1087-1100.
26. Bursten B. & S. Nattel. 2008. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 51: 802-809.
27. Tanaka, K., S. Zlochiver, K.L. Vikstrom, et al. 2007. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ. Res. 101: 839-847.
28. Verheule, S., T. Sato, T. Everett IV, et al. 2004. Increased vulnerability to atrial fibrillation in trans-genic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ. Res. 94: 1458-1465.
29. Pitt, B., E Zannad, W.J. Remme, et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl. J. Med. 341: 709-717.
30. Pitt, B., W. Remme, F. Zannad, et al. 2003. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348: 1309-1321.
31. Ouvrard-Pascaud, A., Y. Sainte-Marie, J.P. Benitah, et al. 2005. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111: 3025-3033.
32. Du, X.J., et al. 2007. Atrial fibrillation and conduction blockade in a mouse model of dilated cardiomyopa-thy with reduced PI3K activity (abstract). Circ. Res. 101: 3.
33. Iles, L. et al. 2008. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52: 1574-1580.